Andy Spencer, Ph.D., is SVP, Preclinical Research and Development responsible for preclinical characterization, non-clinical safety assessment, and DMPK at Spyre. He most recently served on the leadership team at Empirico Inc., a human genetics-driven novel target and drug discovery company. Prior, he served as Senior Vice President of Preclinical Research and Development and as a member of the executive team at Millendo Therapeutics. He was an early employee at Ardelyx, Inc., where he held various senior management roles including VP of Pharmacology and DMPK. At Ardelyx, he served as program manager during the discovery and early development of tenapanor, an FDA-approved treatment marketed as IBSRELA® (for IBS-C patients) and XPHOZAH® (for kidney dialysis patients). Dr. Spencer was a member of the founding team and has served as an advisor to Sling Therapeutics. He received his B.S. in chemistry with honors from Hope College and his Ph.D. in biochemistry from Michigan State University. He completed postdoctoral training at Howard Hughes Medical Institute/University of Colorado and the University of Wisconsin as a fellow of the National Institutes of Health (NIH).